In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BG Medicine gets $40mm through its Series D round

Executive Summary

BG Medicine (molecular diagnostics) has raised $40mm through the closing of its Series D venture round. New investors Legg Mason Capital Management, GE Asset Management, and SmallCap World Fund were joined by returning backers Flagship Ventures, Gilde Healthcare Partners, Humana, and individual investor Stelios Papadopoulos. Leerink Swann was the placement agent. The company, which has raised about $92mm since it was established in 2000, will use the funds to finish development of and market its first two diagnostics--one to distinguish between which heart-failure patients will remain stable and which ones will quickly decline, and another test to determine those that may be at risk of heart attack in the next 2-3 years.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies